A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04520646 |
Recruitment Status : Unknown
Verified August 2020 by Zhaoyun Zhang, Huashan Hospital.
Recruitment status was: Recruiting
First Posted : August 20, 2020
Last Update Posted : August 20, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Acromegaly Cardiomyopathies | Drug: Empagliflozin | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 10 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy |
Estimated Study Start Date : | September 1, 2020 |
Estimated Primary Completion Date : | August 31, 2021 |
Estimated Study Completion Date : | August 31, 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: empagliflozin
empagliflozin is added on the basis of the original treatment
|
Drug: Empagliflozin
empagliflozin of 10mg/day is added on the basis of primary care |
- Left ventricular mass index [ Time Frame: 6 months ]the changes in left ventricular mass index by heart MRI

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patients with pituitary GH adenomas confirmed by surgery
active acromegalic patients although treated with surgery,radiation therapy and somatostatin analogs
Exclusion Criteria:
- patients with contraindications to empagliflozin pregnant patients patients with poor control of hypertension(SBP>150mmHg or DBP>95mmHg patients with contraindications to MRI

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04520646
Contact: Cuiyun Wu | +86(21)52888045 | mhe2004@263.net |
China, Shanghai | |
Huashan Hospital | Recruiting |
Shanghai, Shanghai, China, 200040 | |
Contact: Min He, Doctor +862152887027 mhe2004@263.net | |
Principal Investigator: Zhaoyun Zhang, Professor |
Responsible Party: | Zhaoyun Zhang, vice director of endocrine department, Huashan Hospital |
ClinicalTrials.gov Identifier: | NCT04520646 |
Other Study ID Numbers: |
KY2020-849 |
First Posted: | August 20, 2020 Key Record Dates |
Last Update Posted: | August 20, 2020 |
Last Verified: | August 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Acromegaly Cardiomyopathies Heart Diseases Cardiovascular Diseases Bone Diseases, Endocrine Bone Diseases Musculoskeletal Diseases Hyperpituitarism Pituitary Diseases Hypothalamic Diseases |
Brain Diseases Central Nervous System Diseases Nervous System Diseases Endocrine System Diseases Empagliflozin Sodium-Glucose Transporter 2 Inhibitors Molecular Mechanisms of Pharmacological Action Hypoglycemic Agents Physiological Effects of Drugs |